Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280995 · ClinicalTrials.gov registry record · Phase 2
Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy
A Phase 2 study, sponsored by Kastle Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00280995 is a Phase 2 study that has completed, run by Kastle Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT00280995, a Phase 2 study, has completed, sponsored by Kastle Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 as add-on therapy in subjects with Homozygous Familial Hypercholesterolemia
Interventions
- DRUG ISIS 301012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00280995
The ClinicalTrials.gov registry entry for NCT00280995 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kastle Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ISIS 301012 is the first listed.
NCT00280995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00280995 about?
NCT00280995 is a clinical study titled "Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy". The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 as add-on therapy in subjects with Homozygous Familial Hypercholesterolemia
What is the current status of trial NCT00280995?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2006-01. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00280995?
The interventions under investigation include: ISIS 301012 (DRUG).
Who is sponsoring clinical trial NCT00280995?
This trial is sponsored by Kastle Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.